Table 1 Descriptive statistics of the population samples.
Histopathology annotation available (N = 2162) | TSO500 sequencing available (N = 2134) | Plasma protein data available (N = 128) | |
|---|---|---|---|
Age at diagnosis | |||
Mean (SD) | 69.77 (12.26) | 69.84 (12.19) | 68.91 (11.83) |
Year of diagnosis | |||
Mean (SD) | 2003.25 (10.15) | 2003.36 (10.00) | 2003.23 (2.10) |
Follow-up time | |||
Median (years) | 4.58 | 4.50 | 9.58 |
Sex | |||
Male | 1136 (52.5%) | 1134 (53.1%) | 73 (57.0%) |
Female | 1026 (47.5%) | 1000 (46.9%) | 55 (43.0%) |
Prior cancer diagnosis | |||
No | 1879 (86.9%) | 1857 (87.0%) | 126 (98.4%) |
Yes | 283 (13.1%) | 277 (13.0%) | 2 (1.6%) |
Lynch syndrome | |||
No disease | 2121 (98.1%) | 2086 (97.8%) | 126 (98.4%) |
Disease | 41 (1.9%) | 48 (2.2%) | 2 (1.6%) |
Deceased | |||
Alive | 673 (31.1%) | 655 (30.7%) | 35 (27.3%) |
Deceased | 1489 (68.9%) | 1479 (69.3%) | 93 (72.7%) |
Deaths from CRC | |||
Alive/other | 1442 (66.7%) | 1424 (66.7%) | 93 (72.7%) |
Died from CRC | 720 (33.3%) | 710 (33.3%) | 35 (27.3%) |
Cancer stage (TNM) | |||
I | 272 (12.6%) | 247 (11.6%) | 13 (10.2%) |
II | 801 (37.0%) | 673 (31.5%) | 52 (40.6%) |
III | 710 (32.8%) | 614 (28.8%) | 43 (33.6%) |
IV | 379 (17.5%) | 310 (14.5%) | 20 (15.6%) |
Missing/uncertain | 0 (0%) | 290 (13.6%) | 0 (0%) |
Tumour location | |||
Proximal to splenic flexure | 1014 (46.9%) | 892 (41.8%) | 51 (39.1%) |
Distal to splenic flexure | 1148 (53.1%) | 1242 (58.2%) | 64 (50.0%) |
Missing | 0 (0%) | 0 (0%) | 14 (10.9%) |
Amount of stroma in the tumour | |||
<10% | 768 (35.5%) | 636 (29.8%) | 56 (43.8%) |
10–50% | 841 (38.9%) | 733 (34.4%) | 30 (23.4%) |
>50% | 553 (25.6%) | 466 (21.8%) | 28 (21.8%) |
Not available | 0 (0%) | 299 (14.0%) | 14 (11.0%) |
Lymphocytic infiltrate at the tumour margin | |||
Low–intermediate | 1656 (78.4%) | 1437 (67.3%) | 87 (68.0%) |
High | 466 (21.6%) | 398 (18.7%) | 27 (21.0%) |
Not available | 0 (0%) | 299 (14.0%) | 14 (11.0%) |
Lymphoid follicles | |||
Absent | 1775 (82.1%) | 1506 (70.6%) | 94 (73.4%) |
Present | 387 (17.9%) | 329 (15.4%) | 20 (15.6%) |
Not available | 0 (0%) | 299 (14.0%) | 14 (11.0%) |
TMB/Mb | |||
TMB > 20 | 294 (13.6%) | 305 (14.3%) | 14 (10.9%) |
TMB ≤ 20 | 1541 (71.3%) | 1829 (85.8%) | 80 (62.5%) |
Not available | 327 (15.1%) | 0 | 34 (26.6%) |
%MSI | |||
%MSI > 15 | 269 (12.4%) | 280 (13.1%) | 11 (8.6%) |
%MSI ≤ 15 | 1534 (71.0%) | 1817 (85.1%) | 82 (64.1%) |
Not available | 359 (16.6%) | 37 (17.8%) | 35 (27.3%) |
APC mutation | |||
Present | 1392 (64.4%) | 1625 (76.1%) | 64 (50.0%) |
Absent | 443 (20.5%) | 509 (23.9%) | 30 (23.5%) |
Not available | 327 (15.1%) | 0 | 34 (26.5%) |
KRAS mutation | |||
Present | 769 (35.6%) | 906 (42.5%) | 38 (29.7%) |
Absent | 1066 (49.3%) | 1228 (57.5%) | 56 (43.8%) |
Not available | 327 (15.1%) | 0 | 34 (26.5%) |
TP53 mutation | |||
Present | 1179 (54.5%) | 1401 (65.7%) | 69 (53.9%) |
Absent | 656 (30.4%) | 733 (34.3%) | 25 (19.6%) |
Not available | 327 (15.1%) | 0 | 34 (26.5%) |
BRAF mutation | |||
Present | 327 (15.1%) | 314 (14.7%) | 17 (13.3%) |
Absent | 1744 (80.7%) | 1820 (85.3%) | 94 (73.4%) |
Not available | 91 (4.2%) | 0 (0%) | 17 (13.3%) |
